Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199832 | 1.00 | KMT2A (0.44) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL2202677 | 0.97 | KMT2A (0.46) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL2202671 | 0.97 | KMT2A (0.46) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL2200439 | 0.87 | KMT2A (0.50) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL2200442 | 0.87 | KMT2A (0.50) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL2203081 | 0.85 | PARP1 (0.36) | TP53ALPLPYGLPARP1SMN1; SMN2 | |
| SCHEMBL2203076 | 0.85 | PARP1 (0.36) | TP53ALPLPYGLPARP1SMN1; SMN2 | |
| SCHEMBL2199019 | 0.83 | PARP1 (0.35) | KMT2AMEN1POLBALPLPYGL | |
| SCHEMBL2199024 | 0.83 | PARP1 (0.35) | KMT2AMEN1POLBALPLPYGL | |
| SCHEMBL2199807 | 0.83 | KMT2A (0.48) | KMT2AMAPTMEN1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | KMT2A 4057/4885MAPT 4214/4885MEN1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.